American Journal of Ophthalmology 2014-04-01

Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes.

Ajay E Kuriyan, Kathleen D Weiss, Harry W Flynn, William E Smiddy, Audina M Berrocal, Thomas A Albini, Darlene Miller

Index: Am. J. Ophthalmol. 157(4) , 774-780.e1, (2014)

Full Text: HTML

Abstract

To report the clinical settings, antibiotic susceptibilities, and outcomes of endophthalmitis caused by Streptococcus species.Retrospective, observational case series.Single-center study evaluating all patients with culture-positive endophthalmitis caused by Streptococcus species between January 1, 2000, and December 31, 2011.Study criteria were met by 63 patients. The most common clinical settings were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract surgery (n = 13; 21%). The isolates were Streptococcus viridans (n = 47; 71%), Streptococcus pneumoniae (n = 13; 21%), and β-hemolytic Streptococci (n = 5; 8%). Sixty (95%) of 63 isolates were susceptible to vancomycin, 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93%) of 61 isolates were susceptible to levofloxacin (third-generation fluoroquinolone). Between the first and second half of the study, the minimal inhibitory concentration of antibiotics required to inhibit 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the same for vancomycin. Initial treatment was vitreous tap (49; 78%) or pars plana vitrectomy (14; 22%); all received intravitreal antibiotics. Visual acuity outcomes were variable: best-corrected visual acuity was 20/400 or better in 16 (25%) patients and worse than 20/400 in 47 (75%) patients. Evisceration or enucleation was performed in 16 (25%) patients.Streptococcus isolates generally had high susceptibility rates to commonly used antibiotics. Higher antibiotic minimal inhibitory concentrations were required to inhibit 90% of isolates in vitro in the second half of the study period compared with the first half. Despite prompt treatment, most patients had poor outcomes.Copyright © 2014 Elsevier Inc. All rights reserved.

Related Compounds

Structure Name/CAS No. Articles
Vancomycin Hydrochloride Structure Vancomycin Hydrochloride
CAS:1404-93-9
Ceftazidime Pentahydrate Structure Ceftazidime Pentahydrate
CAS:78439-06-2
Amikacin Structure Amikacin
CAS:37517-28-5
Amikacin sulfate Structure Amikacin sulfate
CAS:39831-55-5